SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chan, C. H. Articles by Levy, S. Search for Related Content PubMed PubMed Citation Articles by Chan, C. H. Articles by Levy, S. Related Collections Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 February 2001, Vol. 97, No. 4, pp. 1023-1026 IMMUNOBIOLOGY VH1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen Chunghuang Hubert Chan, Kenneth G. Hadlock, Steven K. H. Foung, and Shoshana Levy From the Department of Medicine, Division of Oncology and Pathology, Stanford University Medical Center, Stanford, CA.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Hepatitis C virus (HCV)-associated B cell lymphomas were previously shown to express a restricted repertoire of immunoglobulin VH and VL genes, VH1-69 and VA27, respectively. Although this suggests a role for antigen selection in the pathogenesis of these lymphomas, the driving antigen involved in the clonal expansion has not been identified. B cell response to a viral antigen, the HCV envelope glycoprotein 2 (E2), was analyzed in an asymptomatic HCV-infected patient. Single B cells, immortalized as hybridomas and selected for binding E2, were analyzed for their V gene usage. Sequences of these V region genes demonstrated that each hybridoma expressed unique VH and VL genes. Remarkably, these anti-E2 hybridomas preferentially used the VH1-69 gene. Analysis of replacement to silent mutation ratios indicated that the genes underwent somatic mutation and antigenic selection. In a separate report, human anti-E2 antibodies were also shown to express the same VH gene. These data strengthen the hypothesis that the HCV-associated lymphomas are derived from clonally expanded B cells stimulated by HCV. (Blood. 2001;97:1023-1026) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Hepatitis C virus (HCV) is estimated to have infected more than 100 million people globally.1 The study of the natural history of this virus is curtailed because the virus does not infect small laboratory animals, nor can it be propagated in vitro. It is a major cause of chronic liver diseases in which 70% to 80% of infected patients become chronic carriers.2 The liver manifestations of HCV infection include chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.3 Although HCV is a hepatotropic virus, the HCV genome and its replicative intermediates have also been detected in peripheral blood mononuclear cells and in lymphoid tissues of chronically infected patients.4-6 Furthermore, HCV has been recognized as the major causative agent of mixed cryoglobulinemia (MC)70% to 100% of patients with MC are infected by HCV.7-10 MC is a disorder in which monoclonal or polyclonal B cell proliferation is triggered by HCV infection.11-14 It has been proposed that the benign lymphoproliferation associated with MC could lead to frank B cell neoplastic disorders. Indeed, a study from Italy in which 200 patients with MC were followed longitudinally showed that B cell non-Hodgkin lymphoma (NHL) developed in 14 patients.15 However, it should be noted that an association between HCV and B cell NHL has been reported only in certain geographic regions, and the cause of the varied incidence is not yet clear. Immunochemically, MCs are classified as type II or type III, respectively, on the basis of the presence of monoclonal or polyclonal IgM with rheumatoid factors (RF). The monoclonal IgM was shown to be encoded by a restricted set of variable (V) region genes, specifically the VH1-69 (also known as 51p1) and the VA27 (also known as v325) germline genes.16-18 Interestingly, most patients with HCV-associated lymphomas express the same set of genes (VH1-69 and VA27). Furthermore, analysis of these V region sequences revealed that they undergo somatic mutation, presumably during affinity maturation.19 It has, therefore, been proposed that these HCV-associated lymphomas may originate in B cells responding to a common antigen. Nevertheless, such a common antigen has not been identified. We tested whether an immune response to a specific viral antigen is restricted in HCV infection. To this end we analyzed 10 human B cell hybridomas derived from the peripheral B cells of an asymptomatic HCV-infected patient. These hybridomas were selected by reactivity with the viral E2 glycoprotein.20 We demonstrate that the VH genes used by these anti-E2 B cells were highly restricted. Moreover, the same VH gene, VH1-69, seen in HCV-associated lymphomas and in MC is the one used in the anti-E2 immune response. An independent study that used a combinatorial Fab library approach and selected anti-E2 antibodies from an HCV-infected patient showed these antibodies to express the same gene bias.21 These results tie the HCV-associated lymphoproliferative disorders to the immune response to HCV antigens.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Anti-HCV E2 human hybridomas Peripheral B cells were isolated from an asymptomatic patient who had a high serum neutralization binding titer to the HCV 1b viral genotype. Peripheral blood B cells from this patient were activated by Epstein-Barr virus and then electrofused with heteromyeloma cells to produce human hybridomas as described.20 The hybridomas were screened for binding HCV E1/E2 proteins produced by recombinant baculovirus in insect cells. Ten hybridomas were selected, all of which produced an antibody that reacted with the HCV E2 envelope glycoprotein.20 RT-PCR and V region sequencing Total cellular RNA was isolated using the RNeasy mini kit (QIAGEN, Valencia, CA). RNA (4 µg) was reverse transcribed, and V region genes were amplified using 5' family-specific V leader primers and 3' J region primers, as described previously.22 Polymerase chain reaction (PCR) products were electrophoresed, size selected, and sequenced by an automated DNA sequencer (373; Applied Biosystems, Foster City, CA) using the ABI Prism Big Dye Terminator Kit (Perkin Elmer, Foster City, CA). The same primers were used for the original PCR reactions and for sequencing. To control for potential PCR error, all samples were evaluated through 2 independent rounds of PCR reaction and sequencing. Analysis of mutations Sequences were analyzed using MacVector and AssemblyLign (Oxford Molecular Group, Campbell, CA) and aligned with germline sequences using VBASE database and DNA plot on the Internet.23 Somatic mutations were determined by comparison to germline genes with the highest homology (Table 1). The probability (P) of excess or scarcity of replacement (R) mutations in CDR and FR regions was calculated by a multinomial distribution model.24                                View this table: [in this window] [in a new window]   Table 1. Distribution of V gene mutations in anti-HCV E2 hybridomas     Results Top Abstract Introduction Materials and methods Results Discussion References Anti-HCV E2 hybridomas use restricted VH genes Individual B cells from a patient responding to HCV infection were isolated in the form of heterohybridomas. They were selected for reactivity with the viral envelope protein E2.20 Immunoglobulins secreted by 9 of these hybridomas recognized conformational, nondenatured epitopes within E2. The reactive E2 epitope of 5 immunoglobulins prevented binding of E2 to human CD81, the putative cellular receptor for HCV.25 These hybridomas provide a unique opportunity to study a human B cell response to a specific HCV antigen. They enabled us to test whether these responding B cells were derived randomly from the V gene repertoire expressed in normal peripheral blood lymphocytes26-29 or whether they exhibited a biased V gene usage, as seen in the clonal populations in HCV-infected patients with B cell proliferative disorders.16,17,19 To this end, we sequenced V region genes expressed by the hybridomas. This analysis revealed that the VH gene usage was restricted (Figure 1A). Six anti-HCV E2 hybridomas used a VH gene that matched best to germline VH1-69 (also known as 51p1). One additional VH1 hybridoma matched the VH1-e gene, which is highly homologous to VH1-69 because it has only one amino acid difference in FR3 (VH1-e Lys73 vs VH1-69 Glu73) and is considered to be VH1-69-related.30 All 7 hybridomas expressing these VH1 family genes were derived from different B cells because they had unique CDR3 regions. The preferential expression of VH1-69 in anti-HCV E2 hybridomas in 6 (and possibly 7) of 10 patients is exceptionally high. The VH genes encoding the remaining 3 heavy chains were most closely related to VH5-1, VH4-59, and VH3-73 (Figure 1A). All VH genes showed numerous nucleotide differences from their corresponding germline genes (data not shown). View larger version (48K): [in this window] [in a new window]   Figure 1. Deduced amino acid sequences of anti-HCV E2 hybridoma-region genes. (A) VH genes. (B) VL genes. Amino acid sequences of the most homologous germline VH genes are shown above the cloned hybridoma V and VK region sequences. Amino acid replacement mutations are shown as uppercase letters, and silent mutations are indicated by asterisks. VL genes of anti-HCV E2 hybridomas The isotype of the secreted light chain was first determined by enzyme-linked immunosorbent assay (data not shown) and confirmed by reverse transcription (RT)-PCR followed by sequencing (Figure 1B). The usage of VL genes was less restricted than that seen for the VH genes. Only 2 hybridomas used the VA27 light chain, which has been associated with HCV lymphoproliferative disorders. The remaining 8 hybridomas used 6 different light chains. Interestingly, somatic mutations were observed in all VL sequences, but to a lesser extent than seen for the VH sequences. Overall, only one of the hybridomas, CBH-4B, used the canonical VH1-69/VA27 combination seen in MC and in HCV-associated lymphomas. It is unclear why the VH, but not the light-chain V, genes used by these hybridomas resemble the biased V gene usage seen in B cell lymphoproliferative diseases. One likely explanation is that the selection of the hybridomas in vitro was based on reactivity with a recombinant protein, which might have recognized only a subset of B cells induced to proliferate in vivo by the virus. Evidence of antigen selection To address the role of antigen selection in the patient's immune response to the E2 protein, we analyzed the expressed V region genes for the distribution of replacement and silent mutations in CDR and FR regions (Table 1) using a multinomial distribution model.24 Calculated are the probabilities for obtaining replacement to silent mutations (R:S) in CDR and in FR regions by chance alone. A significant excess of R mutations was observed in CDR regions for 8 of 10 VH and 5 of 10 VL sequences, implying positive selection for antigen binding. A significant scarcity of R mutations was seen in FR regions in 9 of 10 VH sequences and in 6 of 10 VL sequences, indicating a negative selection pressure against change in the functional antibody framework structures. Thus, these hybridomas show strong evidence of antigenic selection. Similar biased V gene usage by independent human anti-E2 antibodies A recent study, aimed at isolating the protective antibodies against the HCV E2 protein, used a combinatorial library approach and RNA from another HCV-infected patient. Seven combinatorial Fab fragments, reacting with conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus, were reported.21 We analyzed the V gene usage of these Fab fragments and found them to exhibit biased V gene usage. Three of them expressed the VH1-69 gene (accession numbers AJ236548, AJ236544, AJ236543), and a fourth one expressed the V1-e gene (AJ236542). Preferential usage was also found for the V genes. The VA27 gene was seen in 4 of the antibodies (AJ236555, AJ236552, AJ236551, AJ236549). Interestingly, 2 used the canonical VH1-69-VA27 combination seen in MC and in lymphomas, and a third used the almost identical VH1-e-VA27 combination.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Approximately 1.7% of peripheral blood B cells express the VH1-69 gene,31 as expected for a random use of the total repertoire of functional VH gene regions. As discussed earlier, biased use of this gene has been seen in MC and in HCV-associated B cell lymphomas. Preferential use of this gene has also been seen in 10% to 20% of patients with CD5+ B cell chronic lymphocytic leukemia.32-34 In addition, biased use of VH1-69 has been demonstrated for salivary gland mucosa-associated lymphoid tissue (MALT) lymphomas in which 61% of the patients express the gene.35 Interestingly, MALT lymphomas that develop in the stomach do not show this bias. Taken together, these observations suggest immune stimulation and selection by an antigen that may be located only in the salivary gland for those lymphomas that arise in the salivary gland. The finding that the length of CDR3 is restricted in salivary gland MALT lymphomas, but not in other MALT lymphomas, strengthens this hypothesis.35 Restricted V gene usage combined with restricted CDR3 length has been seen in inbred mice strains responding to experimental vaccination protocols. B cells derived from such immunized mice and selected by reactivity with specific haptens such as 4-hydroxy-3-nitrophenylacetyl (NP),36 2-phenyloxazolone,37 and p-azophenylarsonate38 exhibit a V gene restriction bias. Fewer such studies have been reported in humans. However, studies by Carroll et al39 in volunteers who were vaccinated with the Haemophilus influenzae type b capsular polysaccharide (Hib PS) antigen show a restricted V gene response to this antigen. They reveal a markedly restricted immune response to the Hib PS antigenapproximately half the VH gene rearrangements are of the VH3b subfamily. Moreover, these restricted genes have extremely restricted CDR3 regions in which unrelated patients have identical V(D)J joints. The VL gene response to the Hib PS antigen was less restricted, as seen in the anti-E2 response in the current analysis, suggesting that in both cases the VH gene segments are the ones that play a more dominant role in antigen binding. In summary, HCV-associated type II mixed cryoglobulinemia expresses immunoglobulin encoded mostly by germline VH1-69 and VA27 genes.10,16,17 This same biased use of the VH1-69/VA27 combination was found in HCV-associated lymphomas, indicating that they most likely represent the malignant counterpart of type II MC.15 Finally, our current study and the recent study by Allander et al21 support this hypothesis by demonstrating that human anti-HCV E2 monoclonal antibodies are preferentially encoded by the same V genes. These studies implicate the specific immune response to HCV E2 glycoprotein in the pathogenesis of B cell proliferative disorders and as a precursor to HCV-associated lymphomas. However, to prove directly that an HCV antigen plays a role in lymphomagenesis, it will be necessary to rescue immunoglobulins from HCV-associated lymphomas and to test their ability to bind HCV proteins.     Acknowledgments We thank Dr Ronald Levy for his continuous interest in this project, Dr Izidore Lossos for guidance in the analysis of the distribution of somatic mutations, and Drs Ronald Levy, Izidore Lossos, and Elizabeth Quinn for reviewing the manuscript.     Footnotes Submitted April 24, 2000; accepted October 24, 2000. Supported by National Institutes of Health grants CA34233 (S.L.) and DA06596 and HL33811 (S.K.H.F.). The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Shoshana Levy, Department of Medicine, Division of Oncology, M-207, Stanford University Medical Center, Stanford, CA 94305-5115.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305[Abstract/Free Full Text]. 2. Clarke B. Molecular virology of hepatitis C virus. J Gen Virol. 1997;78:2397-2410[Medline] [Order article via Infotrieve]. 3. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: a case-control study. Ann Intern Med. 1992;116:97-102. 4. Ferri C, Monti M, La Civita L, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood. 1993;82:3701-3704[Abstract/Free Full Text]. 5. Lerat H, Rumin S, Habersetzer F, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood. 1998;91:3841-3849[Abstract/Free Full Text]. 6. Sansonno D, De Vita S, Cornacchiulo V, Carbone A, Boiocchi M, Dammacco F. Detection and distribution of hepatitis C virus-related proteins in lymph nodes of patients with type II mixed cryoglobulinemia and neoplastic or non-neoplastic lymphoproliferation. Blood. 1996;88:4638-4645[Abstract/Free Full Text]. 7. Abel G, Zhang QX, Agnello V. Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum. 1993;36:1341-1349[Medline] [Order article via Infotrieve]. 8. Ferri C, La Civita L, Longombardo G, Greco F, Bombardieri S. Hepatitis C virus and mixed cryoglobulinaemia. Eur J Clin Invest. 1993;23:399-405[Medline] [Order article via Infotrieve]. 9. Ferri C, La Civita L, Zignego AL. Extrahepatic manifestations of hepatitis C virus infection [letter; comment]. Ann Intern Med. 1996;125:344[Free Full Text]discussion 346. 10. Sasso EH. The rheumatoid factor response in the etiology of mixed cryoglobulins associated with hepatitis C virus infection. Ann Med Interne (Paris). 2000;151:30-40[Medline] [Order article via Infotrieve]. 11. De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum. 2000;43:94-102[CrossRef][Medline] [Order article via Infotrieve]. 12. Gorevic PD, Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol. 1991;28:79-94[Medline] [Order article via Infotrieve]. 13. Monteverde A, Rivano MT, Allegra GC, et al. Essential mixed cryoglobulinemia, type II: a manifestation of a low-grade malignant lymphoma? Clinical-morphological study of 12 cases with special reference to immunohistochemical findings in liver frozen sections. Acta Haematol. 1988;79:20-25[Medline] [Order article via Infotrieve]. 14. Perl A, Gorevic PD, Ryan DH, Condemi JJ, Ruszkowski RJ, Abraham GN. Clonal B cell expansions in patients with essential mixed cryoglobulinaemia. Clin Exp Immunol. 1989;76:54-60[Medline] [Order article via Infotrieve]. 15. La Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, Ferri C. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum. 1995;38:1859-1860[Medline] [Order article via Infotrieve]. 16. Andrews DW, Capra JD. Complete amino acid sequence of variable domains from two monoclonal human anti-gamma globulins of the Wa cross-idiotypic group: suggestion that the J segments are involved in the structural correlate of the idiotype. Proc Natl Acad Sci U S A. 1981;78:3799-3803[Abstract/Free Full Text]. 17. Carson DA, Fong S. A common idiotope on human rheumatoid factors identified by a hybridoma antibody. Mol Immunol. 1983;20:1081-1087[CrossRef][Medline] [Order article via Infotrieve]. 18. Sasso EH, Johnson T, Kipps TJ. Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest. 1996;97:2074-2080[Medline] [Order article via Infotrieve]. 19. Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood. 1998;91:2433-2442[Abstract/Free Full Text]. 20. Hadlock GH, Lanford RE, Perkins S, et al. Human monoclonal antibodies to highly conserved domains on hepatitis C virus E2 protein. J Virol. 2000;74:10407-10416[Abstract/Free Full Text]. 21. Allander T, Drakenberg K, Beyene A, et al. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol. 2000;81:2451-2459[Abstract/Free Full Text]. 22. Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol. 1992;29:193-203[CrossRef][Medline] [Order article via Infotrieve]. 23. Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunol Today. 1995;16:237-242[CrossRef][Medline] [Order article via Infotrieve]. 24. Lossos IS, Tibshirani R, Narashimhan B, Levy R. The inference of antigen selection on immunoglobulin genes. J Immunol. 2000;165:5122-5126[Abstract/Free Full Text]. 25. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938-941[Abstract/Free Full Text]. 26. Bessudo A, Rassenti L, Havlir D, Richman D, Feigal E, Kipps TJ. Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood. 1998;92:1317-1323[Abstract/Free Full Text]. 27. Brezinschek HP, Brezinschek RI, Lipsky PE. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol. 1995;155:190-202[Abstract]. 28. Guigou V, Cuisinier AM, Tonnelle C, Moinier D, Fougereau M, Fumoux F. Human immunoglobulin VH and VK repertoire revealed by in situ hybridization. Mol Immunol. 1990;27:935-940[CrossRef][Medline] [Order article via Infotrieve]. 29. Logtenberg T, Schutte ME, Inghirami G, et al. Immunoglobulin VH gene expression in human B cell lines and tumors: biased VH gene expression in chronic lymphocytic leukemia. Int Immunol. 1989;1:362-366[Abstract/Free Full Text]. 30. Cook GP, Tomlinson IM, Walter G, et al. A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q. Nat Genet. 1994;7:162-168[CrossRef][Medline] [Order article via Infotrieve]. 31. Brezinschek HP, Brezinschek RI, Dorner T, Lipsky PE. Similar characteristics of the CDR3 of V(H)1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells. Br J Haematol. 1998;102:516-521[CrossRef][Medline] [Order article via Infotrieve]. 32. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525[Medline] [Order article via Infotrieve]. 33. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia [see comments]. Blood. 1999;94:1848-1854[Abstract/Free Full Text]. 34. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997;158:235-246[Abstract]. 35. Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood. 2000;95:3878-3884[Abstract/Free Full Text]. 36. Krawinkel U, Cramer M, Melchers I, Imanishi-Kari T, Rajewsky K. Isolated hapten-binding receptors of sensitized lymphocytes, III: evidence for idiotypic restriction of T-cell receptors. J Exp Med. 1978;147:1341-1347[Abstract/Free Full Text]. 37. Kaartinen M, Griffiths GM, Markham AF, Milstein C. mRNA sequences define an unusually restricted IgG response to 2-phenyloxazolone and its early diversification. Nature. 1983;304:320-324[CrossRef][Medline] [Order article via Infotrieve]. 38. Milner EC, Capra JD. VH families in the antibody response to p-azophenylarsonate: correlation between serology and amino acid sequence. J Immunol. 1982;129:193-199[Abstract]. 39. Carroll WL, Shackelford PG, Adderson EE. The immunoglobulin gene repertoire to Haemophilus influenzae type b. Ann N Y Acad Sci. 1995;764:374-377[Medline] [Order article via Infotrieve]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Saadoun, D. A. Landau, L. H. Calabrese, and P. P. Cacoub Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation Rheumatology, August 1, 2007; 46(8): 1234 - 1242. [Abstract] [Full Text] [PDF] T. Naas, M. Ghorbani, I. Alvarez-Maya, M. Lapner, R. Kothary, Y. De Repentigny, S. Gomes, L. Babiuk, A. Giulivi, C. Soare, et al. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2 J. Gen. Virol., August 1, 2005; 86(8): 2185 - 2196. [Abstract] [Full Text] [PDF] M. Carbonari, E. Caprini, T. Tedesco, F. Mazzetta, V. Tocco, M. Casato, G. Russo, and M. Fiorilli Hepatitis C Virus Drives the Unconstrained Monoclonal Expansion of VH1-69-Expressing Memory B Cells in Type II Cryoglobulinemia: A Model of Infection-Driven Lymphomagenesis J. Immunol., May 15, 2005; 174(10): 6532 - 6539. [Abstract] [Full Text] [PDF] D. Vallisa, P. Bernuzzi, L. Arcaini, S. Sacchi, V. Callea, R. Marasca, A. Lazzaro, E. Trabacchi, E. Anselmi, A. L. Arcari, et al. Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience J. Clin. Oncol., January 20, 2005; 23(3): 468 - 473. [Abstract] [Full Text] [PDF] A. Ahmad and F. Alvarez Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis J. Leukoc. Biol., October 1, 2004; 76(4): 743 - 759. [Abstract] [Full Text] [PDF] Z.-Y. Keck, A. Op De Beeck, K. G. Hadlock, J. Xia, T.-K. Li, J. Dubuisson, and S. K. H. Foung Hepatitis C Virus E2 Has Three Immunogenic Domains Containing Conformational Epitopes with Distinct Properties and Biological Functions J. Virol., September 1, 2004; 78(17): 9224 - 9232. [Abstract] [Full Text] [PDF] E. H. Sasso, M. Martinez, S. L. Yarfitz, P. Ghillani, L. Musset, J.-C. Piette, and P. Cacoub Frequent Joining of Bcl-2 to a JH6 Gene in Hepatitis C Virus-Associated t(14;18) J. Immunol., September 1, 2004; 173(5): 3549 - 3556. [Abstract] [Full Text] [PDF] Z.-Y. Keck, V. M. H. Sung, S. Perkins, J. Rowe, S. Paul, T. J. Liang, M. M. C. Lai, and S. K. H. Foung Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity J. Virol., July 1, 2004; 78(13): 7257 - 7263. [Abstract] [Full Text] [PDF] E. Zucca, A. Conconi, E. Pedrinis, S. Cortelazzo, T. Motta, M. K. Gospodarowicz, B. J. Patterson, A. J. M. Ferreri, M. Ponzoni, L. Devizzi, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue Blood, April 1, 2003; 101(7): 2489 - 2495. [Abstract] [Full Text] [PDF] O. Hermine, F. Lefrere, J.-P. Bronowicki, X. Mariette, K. Jondeau, V. Eclache-Saudreau, B. Delmas, F. Valensi, P. Cacoub, C. Brechot, et al. Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection N. Engl. J. Med., July 11, 2002; 347(2): 89 - 94. [Abstract] [Full Text] [PDF] P. Algara, M. S. Mateo, M. Sanchez-Beato, M. Mollejo, I. C. Navas, L. Romero, F. Sole, M. Salido, L. Florensa, P. Martinez, et al. Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course Blood, February 15, 2002; 99(4): 1299 - 1304. [Abstract] [Full Text] [PDF] E. R. Quinn, C. H. Chan, K. G. Hadlock, S. K. H. Foung, M. Flint, and S. Levy The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis Blood, December 15, 2001; 98(13): 3745 - 3749. [Abstract] [Full Text] [PDF] R. Marasca, P. Vaccari, M. Luppi, P. Zucchini, I. Castelli, P. Barozzi, A. Cuoghi, and G. Torelli Immunoglobulin Gene Mutations and Frequent Use of VH1-69 and VH4-34 Segments in Hepatitis C Virus-Positive and Hepatitis C Virus-Negative Nodal Marginal Zone B-Cell Lymphoma Am. J. Pathol., July 1, 2001; 159(1): 253 - 261. [Abstract] [Full Text] [PDF] G. Knight, V. Agnello, M. Boiocchi, V. De Re, D. Gasparotto, and S. De Vita WA monoclonal rheumatoid factors and non-Hodgkin lymphoma Blood, May 15, 2001; 97(10): 3319 - 3321. [Full Text] [PDF] This Article